Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of cytochrome P450 2C83 (CYP2C83) in paclitaxel metabolism and paclitaxel-induced neurotoxicity.

Pharmacogenomics - 1 Jan 2015

Lee Mi-Young, Apellániz-Ruiz María, Johansson Inger, Vikingsson Svante, Bergmann Troels K, Brøsen Kim, Green Henrik, Rodríguez-Antona Cristina, Ingelman-Sundberg Magnus

Abstract excerpt

AIM: The CYP2C8*3 allele has been suggested as a risk factor for paclitaxel-induced neuropathy but the data hitherto published are conflicting. MATERIALS & METHODS: In total 435 patients were investigated with respect to maximum neuropathy grade and accumulated paclitaxel dose. The enzymatic properties of CYP2C8.3 variant were analyzed using heterologous mammalian HEK293 cell expression system. RESULTS: No...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amodiaquine
Share to Antineoplastic Agents, Phytogenic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Aryl Hydrocarbon Hydroxylases

Share to Cytochrome P-450 CYP2C8

Share to Neurotoxicity Syndromes

Share to Paclitaxel

Share to Rosiglitazone

Share to Thiazolidinediones

Source

Identifiers

PMID: 26115084
DOI: 10.2217/pgs.15.46

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of cytochrome P450 2C8*3 (CYP2C8*3) in paclitaxel metabolism and paclitaxel-induced neurotoxicity.PMID 26115084Read ↗

CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel.Semantic proximity Read ↗

Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity.Semantic proximity Read ↗

CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity.Semantic proximity Read ↗

Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy.Semantic proximity Read ↗

CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel.Semantic proximity Read ↗

Whole-Exome Sequencing Reveals Defective CYP3A4 Variants Predictive of Paclitaxel Dose-Limiting NeuropathySemantic proximity Read ↗

Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies.Semantic proximity Read ↗

Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: A systematic review.Semantic proximity Read ↗

Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid.Semantic proximity Read ↗

Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer.Semantic proximity Read ↗

Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer.Semantic proximity Read ↗

Functional characterization of CYP2C8.13 and CYP2C8.14: catalytic activities toward paclitaxel.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.